Braeburn's Buprenorphine Bid: Eight Dosing Options Part Of "All Hands On Deck" Approach

With an FDA decision on its buprenorphine injection expected by Jan. 19, Scrip spoke with Braeburn executives at J.P. Morgan about the company's justification for four once-weekly and four once-monthly doses, competition in the opioid use disorder (OUD) market and the need for more OUD therapies.

Compliance medicine health care integration computing concept. Doctor touched icon compliance gear on virtual screen. Medical governance automation robotic modernization healthy strategy, technology

As Braeburn Pharmaceuticals Inc. nears the finish line in the race to bring a buprenorphine injection to market for opioid use disorder (OUD) with a US FDA approval decision for its CAM2038 expected by Jan. 19, company executives are optimistic about the drug's prospects, including the therapy's eight proposed doses.

Scrip spoke with Princeton, NJ-based Braeburn's President and CEO Mike Derkacz as well as Chief Financial Officer David McIntyre in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip